Introduction
Acute pancreatitis (AP) is a common inflammatory disorder that is mild and self-limiting in 80% of cases but which, when severe, may necessitate intensive care admission and lead to organ failure and death. The majority of cases are secondary to either gallstones or alcohol, although a multitude of causes exist. It is a common disease (current UK incidence: 150-420 cases per million per annum) and increasingly prevalent. 1 However, despite recent improvements in intensive care unit management and techniques of organ support, the severity and mortality associated with AP has not decreased since the 1970s 1 : up to 25% of patients will be diagnosed with severe disease [2] [3] [4] [5] and approximately 4% of all patients will die. 6, 7 This can be partly explained by the fact that no specific prophylactic or therapeutic agent is available, and current management is largely supportive. Better understanding of the molecular drivers of AP is essential for the identification of new therapeutic strategies.
Single-nucleotide polymorphisms (SNPs) are single base-pair variants in the DNA sequence which occur with a population frequency of >1%. Associated biological impacts may resultfor instance, if the SNP alters an amino acid in the protein transcribed (thus affecting protein structure and function), or if the SNP lies in a region which affects gene transcription or mRNA stability. Associating such functional variants with specific disease
phenotypes is thus one means by which to infer a causal role for the gene product in disease pathogenesis. Gene-association studies, performed to assess the molecular drivers of pancreatitis (Table 1) , have generally focussed on the activation of pancreatic enzymes and pro-enzymes (one of the key steps in the initiation and propagation of pancreatic inflammation) or the process of systemic inflammation secondary to acute pancreatitis. However, small cohorts have weakened the ability to detect associations in mixed patient groups.
The renin-angiotensin system (RAS), originally described as a key regulator of intravascular homeostasis, controlling extracellular fluid volume and blood pressure, 18 represents a potential target of such gene-association studies. In response to decreased afferent arteriolar pressure, decreased filtered sodium load or sympathetic nervous stimulation, the renal juxtaglomerular apparatus releases renin, 19 which cleaves hepatically-derived angiotensinogen 20 to yield angiotensin I (ang I). Angiotensin-converting-enzyme (ACE) subsequently hydrolyses ang I to yield the effector peptide angiotensin II (ang II) 21 , whose effects are mediated through 2 specific human receptors: the angiotensin II type 1 and 2 receptor (AT 1 R and AT 2 R). 22 However, local renin-angiotensin systems are now known to exist in diverse cells and tissues, including the pancreas, 23, 24 where they have paracrine and autocrine roles in the regulation of metabolism, blood flow, inflammation and healing. [25] [26] [27] Within the pancreas, local generation of ang II influences exocrine and endocrine function through activation of the AT 1 R, stimulating increases in pancreatic enzyme secretion 28, 29 , while reducing islet blood flow and delaying insulin release. [30] [31] [32] It is also implicated in the initiation and propagation of AP. Increased expression of RAS components is identified in experimental models of AP, 33, 34 where they drive activation of monocytes and macrophages, 35, 36 and expression of pro-inflammatory molecules such as interleukin-6 (IL-6), nuclear factor-κβ (NF-κβ) and monocyte chemoattractant protein-1 (MCP-1). 37 Such pro-inflammatory effects may occur through a number of possible AT 1 R-mediated mechanisms including generation of reactive oxygen species, matrix metallopeptidase-9 (MMP-9), nicotinamide adenine dinucleotide phosphate (NADPH), NF-κβ, tumour growth factors (TGFs) and Smad, as well as activation of human pancreatic stellate cells. [37] [38] [39] [40] [41] [42] RAS inhibition has also been shown to attenuate the expression of pro-inflammatory molecules and mitigate pancreatic cellular injury. 43, 44 Further, vitamin D may influence RAS activity by suppressing renin synthesis at the transcriptional level, thus acting as a negative regulator of the RAS. [45] [46] [47] [48] [49] The association of AP (and its severity) with specific variants in key RAS/Vitamin D pathway genes would infer a causal role for such systems in AP pathogenesis. Given the postulated role for RAS/Vit D in AP pathogenesis, we hypothesized that such gene associations would be identified. We thus sought association of common functional variants in the RAS and Vitamin D systems with AP, and its severity, in order to clarify the possible role for RAS in AP pathogenesis; and in particular to elucidate whether genotypes associated with higher RAS activity were associated with the development or severity of acute pancreatitis. 51 ).
Methods

Subjects
Controls were 2766 (2711 following quality control) healthy UK Caucasian males who had participated in the second Northwick Park Heart Study (NPHSII) (aged 51 to 60 years, recruited from 9 general medical practices within the UK) for assessment of ACE (rs4646996) and CYP2R1 (rs10741657) genotypes, and 5059 (1334 women and 3725 men) UK civil servants from the Whitehall II study (WHII; aged 35-55 years and working in the London offices of 20 Whitehall departments) 52 for analysis of other genetic variants. Full details of the genotyping and quality control have been published previously. 53 In summary, DNA from WHII was extracted from 6156 individuals from whole blood samples using magnetic bead technology (Medical Solutions, Nottingham, UK) and normalised to a concentration of 50ng/μl. Custom SNP arrays were designed by the Institute of Translational Medicine and Therapeutics, the Broad Institute and the National Heart Lung and Blood Institute supported Candidate-gene Association Resource Consortium (HumanCVD BeadChip) 54 on 5592 of these samples. After restriction to White/European groups and quality control, 5059 samples were utilised for analysis. Seven hundred and seventeen samples were also obtained from blood-bank donors within the Netherlands and utilised as controls for all genotypes (kindly provided by Prof. C. Wijmenga, Department of Genetics, University Medical Center Groningen, Groningen, the Netherlands.
Genetic Analysis
DNA was extracted from UK subjects utilising the 'salting-out' technique 55 ; from German subjects using Qiagen® DNA extraction kits (Qiagen, Hilden, Germany); and using the DNA isolation kit I from the Magna Pure LC (Roche Diagnostics, Indianapolis, USA) for the Dutch cohort. Common functional polymorphisms in genes of the human RAS and Vitamin D systems, or those previously associated with pancreatic disease, were selected by review of the published literature (Table 2) . Subjects were genotyped for all pre-selected variants, with genetic analysis performed at University College London (London, UK).
DNA was measured and standardised using a Nanodrop® 8000 (Thermo Scientific; Waltham, Ma, USA) spectrophotometer and Beckman Coulter Biomek® 2000 (Biodirect; Taunton, Ma, USA) respectively, to a concentration of 15ng/μl stock, prior to further dilution to 5ng/μl working stocks. The ACE insertion/deletion polymorphism was assessed via initial PCR amplification of DNA and subsequent identification of differences in DNA size utilising 7.5% microplate array diagonal gel electrophoresis (MADGE). The remaining genotypes were determined by polymerase chain reaction amplification (PCR), utilising custom-prepared TaqMan® SNP genotyping assay kits (Applied Biosystems; Carlsbad, CA, USA).
Statistical Analysis
Patient data were anonymised. Allele frequencies were tested for deviation from HardyWeinberg equilibrium using a χ 2 goodness-of-fit test and all allele frequencies were in keeping with existing published population data. Odds ratios and p values were calculated for an additive genetic effect using logistic regression models with adjustment for age, sex and region. For ACE and rs5707 genotypes we also tested the recessive model. Analysis was performed using Stata Version 11 (StataCorp, Texas, USA) and a p value of < 0.05 was considered statistically significant. No adjustment was made for multiple comparisons. Power calculations were performed using Quanto (http://hydra.usc.edu/gxe/). Detectable odds ratios were calculated for the sample size of 544 cases assuming an additive effect. In addition we calculated the number of AP cases that would be required to detect an effect of the size observed in this study. The ratio of controls to cases was 5.4 for (rs4646996) and CYP2R1 (rs10741657), 1.4 for AT 2 R (rs1403543) and AGT (rs699) and 10.6 for the remaining SNPs.
Results
Combined study groups (Table 3) Five hundred and forty-four Caucasian patients (304 [55.9%] male) with acute pancreatitis (UK n=22, Germany n=136, Netherlands n=386), and 8487 control subjects (UK NPHS-II n=2711, UK WHII n=5059, Netherlands n=717) were genotyped. Median patient age was 56 years (17-91years). Two hundred and sixty nine (49.5%) cases were secondary to biliary disease, 118 (21.7%) to alcohol and 157 (28.9%) to other causes. One hundred and seventy three (31.8%) patients overall had severe acute pancreatitis (based upon revised Atlanta criteria 51 ; UK n=4, Germany n=65, Netherlands n=104) and 38 (7.0%) died (Germany n=18 and Netherlands n=20). Infected necrosis occurred in 58 (14.2%) patients in UK and Dutch cohorts (UK n=2 and Netherlands n=56). Data on infected necrosis were not available in the German cohort. Genotype distributions for cases and controls are shown in Table 4 for the overall cohort. The G allele of the renin rs5707 SNP was associated with AP (p=0.003), infected necrosis (p=0.02) and mortality (p=0.003) in the Dutch cohort, where 60% of deaths occurred secondary to infected necrosis (Table 5 ). These findings were replicated when the cohorts were combined (AP (OR (95% CI) = 2.19 (1.34-3.60) p=0.002), infected necrosis (2.75 (1.13-6.68) p=0.025) and mortality (2.66 (1.02-6.95) p=0.046) for the recessive model).
There were no other significant genotype associations with the development of AP, severe AP or mortality from AP.
Alcohol-related acute pancreatitis
One hundred and eighteen patients (21.7% of total) had alcohol-related AP ( 
Discussion
To our knowledge, this is the largest study thus far investigating the association of RAS genotype with acute pancreatitis. The human ACE gene has a genetic variant in which the absence (Deletion, D allele) rather than the presence (Insertion, I allele) of a 287 base pair fragment is associated with higher circulating 65 and tissue ACE activity such as that in myocardium, 66 and inflammatory cells. 67 Our analysis of 544 AP patients and 8487 controls demonstrated an association of the ACE I allele (lower ACE activity) with alcohol-related acute pancreatitis. To date, no other studies have identified an association of ACE genotype with the development or severity of acute, 68 chronic, 69-72 familial 70 or tropical calcific pancreatitis. 73 However, these studies were small, incorporated mixed aetiologies and disease-types (acute, chronic, familial and tropical calcific pancreatitis), and did not address other RAS variants (see Table 8 Table 4 ) as the sample size utilised here only had sufficient power to detect an odds ratio in the range of 1.20-1.26.
Alcohol has also been shown to directly activate RAS in animal models of alcoholic cardiomyopathy. 74 Despite this, our study demonstrated an association of the ACE I allele (lower ACE activity) rather than the postulated D-allele (i.e. high activity) with alcoholrelated acute pancreatitis. This finding seems contrary to the hypothesis that increasing activity of the RAS may lead to increasing likelihood of developing acute pancreatitis or severe disease. However, ACE inhibitor use has been associated with pancreatitis, 75 and multiple angiotensin I processing enzymes are now known to exist (e.g. chymase, chymotrypsin, tonin, aminopeptidase A, B and N, prolylendopeptidase, and neutral endopeptidase). Further, ACE 2, a homologue of ACE with 42% sequence homology 76 has recently been discovered and its primary product, Ang (1-7), acts through the Mas receptor 77 to negatively regulate the RAS; thereby counter-balancing ACE action. Thus, ACE levels, as assessed by RAS genotypes, may not truly represent overall RAS or ACE activity at a local or systemic level, and further studies may require serum assays or pancreatic biopsy samples for direct assessment of tissue ACE levels.
When the cohorts were combined, the renin rs5707 G allele was associated with AP (p=0.002), infected necrosis (p=0.025) and mortality (p=0.046). The renin rs5707 G allele has previously been associated with hypertension and diabetes, and has been hypothesised to increase the activity of the RAS. 60 Although multiple causes exist, a common pathophysiological pathway in AP involves premature activation of various proteolytic pancreatic enzymes such as trypsin, chymotrypsin, carboxypeptidase and kallikrein. Chymotrypsin is capable of converting angiotensinogen to ang I, and trypsin to catalyse ang II to ang III and IV. 78 Therefore, pancreatic enzyme activity may be another crucial factor in the activation of RAS during AP-an effect which may swamp that of RAS genotype. Further, the activation of this common AP-initiating pathway occurs via different mechanisms in biliary-and alcoholrelated pancreatitis, and the heterogeneous proportion of each in the three cohorts may further explain the inconsistency of genetic association between the cohorts from various geographical regions (UK: 40.9% ETOH, 36.4% biliary, 22.7% other; Netherlands: 18.7% ETOH, 54.1% biliary, 27.2% other; Germany: 27.2% ETOH, 39.0% biliary, 33.8% other).
However, although this finding was also present in the Dutch cohort, we could not replicate this finding in cohorts from other countries. Nor was there biological consistency through disease association with other RAS genotypes, or those of (the putatively RAS-regulatory) Vitamin D system investigated here. Such lack of consistency and replication is likely to be secondary to heterogeneity in AP causation
However, such data must be interpreted with caution, and cannot be taken as proof of a role for RAS or Vitamin D in the genesis or severity of AP, perhaps in part due to the study limitations, including the problem of multiple comparison and a relatively small sample size, but also possibly in part due to heterogeneity of AP causation and variations in clinical course. Adjustment for multiple comparison, whilst necessary, may also make the discarding of a 'true positive' finding more likely than that of a 'false positive'. In addition, uniformity in assessment of disease severity is difficult to achieve, 79 and heterogeneity, by its definition, will also weaken power in genetic studies. Further studies should concentrate on large, well-structured study cohorts with clear phenotypes and substantial numbers of individuals in any aetiological group, as well as with tight coconstraints on defined severity, in order to circumvent these issues. In addition, association of any phenotype with one allelic variant may, of course, occur by chance. In addition, the gene variant under study may (through strong linkage disequilibrium) mark activity in an adjacent gene (through which any observed associations are in fact mediated). For reasons such as this, findings of candidate gene association studies require replication if to be considered robust, with subsequent fine-mapping of the genes required.
Further studies should concentrate on large, well-structured study cohorts with clear phenotypes, to attempt to circumvent these issues. However, the association of two RAS polymorphisms ACE I and Renin rs5707 G ACE I with AP in this study does suggest that this issue warrants further detailed analysis, given the ready potential for pharmacological manipulation of this system using existing marketed agents. Such roles are also worthy of active investigation in diverse pancreatic disease states.
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Interleukin - Table 2 A table demonstrating further information on the genetic variants investigated in this study. All variants listed here have previously been associated directly with RAS, indirectly with RAS (vitamin D-metabolising system), or with forms of pancreatic disease. Allele frequencies are based on Caucasian data from HapMap and ABI AoD. Table 3 Baseline characteristics of the 3 study cohorts under investigation. Table 4 Comparison of genotype frequency between combined AP cohorts and controls. Effect of Renin G allele upon outcome from acute pancreatitis in Dutch AP samples and controls. Table 5b Effect of Renin G allele upon outcome from acute pancreatitis in combined cohort samples and controls. 
